JW Holdings

Sep, 2019

JW Pharmaceutical exports 80 billion won worth of technology to Simcere, China.

- Concluded license-out agreement for gout treatment URC102.​​

- URC102, A new drug candidate effective for gout with decreased renal elimination of uric acid, demonstrated high safety and reduced level of uric acid in the blood

May, 2019

60th Anniversary seminar of Korean-Denmark diplomatic relations.

- Introduction of open innovation partnership strategy with Leoparm, a global leader in the field of skin disease.

Oct, 2018

Establishment of strategic partnerships/investments with overseas ventures discovering first-in-class drugs.​​​

- Signed a strategic investment agreement with Argonaut developing a next-generation anticancer drug based on epigenetics​

Aug, 2018

JW Pharmaceutical exports 450 billion won worth of technology to LeoPharma.​​

- Concluded license-out agreement for atopic dermatitis drug candidate, JW1601, with LEO Pharma

- Introduced as "Open Innovation Case" at the 60th anniversary of Korea-Denmark diplomatic relations and received Korea Patent Technology “King Sejong” Grand Prize Award​

July, 2018

Collaboration research agreement on new drugs between C&C Research Laboratories and A^*STAR, Singapore​

- "Development of new global innovative drugs (immunological disease and anticancer drugs)" in cooperation with four research institutes under A^*STAR and National Skin Centre​​

- Discussion of research progress / plan through the steering committee meeting twice a year as a collaboration research for three years (2018 ~ 21)

Establishment of research network with KOLs in the field of Wnt

- Held a regular symposium with the leading Wnt researchers in Korea

- Operation of the SAB (Scientific Advisory Board) composed of overseas prominent Wnt researchers